Valink Therapeutics

+44%

est. 2Y upside i

HealthcarePre-Seed

Discovering bispecific antibody drug-conjugates (BsADC) against cancer

Rank

#1093

Sector

Biotechnology

Est. Liquidity

~3Y

Data Quality

Data: Low

Valink Therapeutics offers high-risk, high-return potential.

Last updated: July 19, 2026

Bull (10%)+375%

Strong preclinical data leads to high-value partnership or Series A at 5x valuation ($150M). Dilution of 25% reduces net upside to 375%.

Base (55%)+75%

Moderate progress to IND enables Series A at 2x valuation ($60M). Dilution trims net return to 75%.

Bear (35%)-100%

Pipeline failure or financing issues lead to shutdown; common equity is wiped out by $20.5M preference stack.

Est. time to liquidity~3.0 years

Preference Stack Risk

severe

Funding Intensity

6830%

Total preferred liquidation preference of $20.5M represents 68% of estimated entry valuation ($30M), implying common stock is deeply subordinate.

Dilution Risk

high

Expected Series A financing within 2 years will dilute common shareholders by approximately 25%.

Secondary Liquidity

none

No secondary market exists; equity is illiquid until an exit event (IPO or acquisition).

Other — 4 roles

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Valink Therapeutics's data — designed to show you've done your homework.

1
“How does the LiliumX™ platform differentiate from existing bispecific ADC approaches?”
2
“What is the expected timeline to IND and how does the company plan to finance clinical trials?”
3
“Given the high total funding relative to valuation, what is the realistic path to positive returns for common stock?”

Our model estimates +44% upside. What do you think?

Anonymous. Do not share material non-public information.

Comments are reviewed before they appear publicly.

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.